We performed a retrospective study in patients who underwent high-dose chemotherapy and auto-SCT because of haematological malignancies. Forty patients were treated with palifermin while 80 were controls selected after being matched for diagnosis and length of neutropenia. Patients treated with BEAM or BU-CY or THIO-CY (BEAM/BUS) displayed, after palifermin, a lower rate of severe oral mucositis (P = 0.03). This beneficial effect of palifermin was not evident in the stratum of patients treated with high-dose melphalan (HD-PAM). After palifermin, we observed in the whole treated population a reduced rate of 'fever of unknown origin' (FUO, P = 0.02) and of severe infections not related to Gram-positive bacteria (FUO, Gram-negative bacteremia or pneumonia) (P = 0.003). This effect of palifermin on infections not related to Gram-positive bacteria was evident only in patients receiving BEAM/BUS (P = 0.01) and not in patients treated with HD-PAM (P = 0.11). Fibrinogen peak in plasma was found to be reduced after palifermin in the whole population (P = 0.01) and in the stratum who received BEAM/BUS (P = 0.02) but not in the stratum of HD-PAM. In conclusion, antiinfectious beneficial effects of palifermin are more evident in BEAM/BUS-treated patients and toward some types of infections. Reduction of fibrinogen level after palifermin suggests that this agent reduces not only the rate of infections but also their severity.
INTRODUCTION
After high-dose chemotherapy and auto-SCT, infectious complications affect 60-90% of patients and are responsible for the mortality rate in 2-3%. [1] [2] [3] Palifermin has been demonstrated, in a controlled randomized study, to have a beneficial effect not only on the prevention of severe oral mucositis but also on the infection rate. 4 This effect has been reported also after conditioning based on chemotherapy. 5 The effect of palifermin on infections is, however, controversial and, in fact, some studies did not report an anti-infection effect after palifermin treatment. [6] [7] [8] These discrepancies may depend on the type of conditioning used. The importance of conditioning is suggested, in fact, by studies from Herbers et al. who reported that palifermin administration in patients treated using a BEAM conditioning schedule leads to a reduction in the rate of some infections such as 'fever of unknown origin' (FUO), 9 while the same group did not find this effect in patients treated with high-dose melphalan (HD-PAM). 10 In a previous work we indeed found that conditioning significantly interacts with the effects of palifermin and that this agent is able to reduce the rate of severe mucositis only after conditioning based on BEAM or on BU/Thiothepa treatment but not after 'HD-PAM' conditioning. 11 Now we present an analysis in which we have assessed the effect of palifermin on infection risk according to the conditioning regimen used. Hence, our results indicate that conditioning regimens significantly interact with the effects of palifermin on infections and that this agent is useful in the prevention of infections after high-dose chemotherapies based on BEAM or BU/ Thiotepa.
PATIENTS AND METHODS

Study design
The study was focused on a total of 120 patients who underwent highdose chemotherapy and autologous hematopoietic SCT during 2000-2009 in our institution because of hematological malignancies. We compared a cohort of patients who received prophylaxis with palifermin (n = 40) with a matched control group of patients who did not receive this agent (n = 80). 
Patients
Two control patients, matched for diagnosis and length of neutropenia after HSC infusion, were selected for each palifermin -treated patient. These two factors are notoriously important for the development of infections.
The demographic features of the patients in the two groups are reported in Table 1 and, as expected, the two sets of patients were fully comparable with the two factors used for matching and also for other pretransplant features.
High-dose chemotherapy and patient care
All patients were extensively studied before transplantation with pulmonary, heart and liver-function tests, and infectious status assessment. Comorbidity score 12 before transplant was available for 97/120 patients. The conditioning used was 'high-dose PAM' (n = 72) or 'other conditioning' (n = 48)-namely, BEAM (n = 33), BU-CY (n = 13) or THIO-CY (n = 2). We refers to 'other conditioning' as 'BEAM/BUS'. Prophylactic anti-infectious measures comprised isolation in a single room equipped with HEPA filtered air, oral non-absorbable antibiotic and anti-mycotic, and systemic prophylactic antibiotic either by oral or by parenteral route. Fluconazole was administered from the end of conditioning during the neutropenic phase, while acyclovir was administered from the start of conditioning for at least 3 months after infusion.
Prophylactic G-CSF was administered during the aplastic phase, according to a controlled institutional study starting at day +5.
Palifermin
Palifermin was administered at the dose of 60 mcg/kg by i.v. push injection daily for a total of six doses. The first three daily doses were administered in outpatients, finishing 24 h before the start of conditioning treatment, and the second set of three doses was started on the day of HSC infusion 48 h after the end of a conditioning treatment. The study was approved by our ethical review board and informed consent was obtained from each patient.
Patients monitoring and work-up and infection definition
Afebrile patients were monitored weekly by blood cultures, serum galactomannan assay, and skin and oral culture swabs. The standard work-up for a febrile patient was used and comprised multiple and repeated blood and urine cultures as well as immediate chest X ray. Patients were also studied with a CT scan of thorax after 72 h of fever. Infections arising during first 30 days after infusion were studied.
FUO was defined as fever 438.2°C for at least 12 h or a single temperature elevation above 38.5°C without bacteremia or evidence of localized infection, microbiologically or clinically documented.
'Pneumonia' was defined as fever and/or symptoms of the respiratory system with focal or diffuse radiological signs of lung infection. Fluid overload had to be excluded when diffuse radiological findings were found.
'Febrile Gram-positive bacteremia' was defined as at least two positive blood cultures drawn on separate occasions and showing isolation of Gram-positive bacteria in afebrile patients.
'Infections not related to Gram-positive bacteria' were defined as FUO or pneumonia or Gram-negative bacteremia.
'CVC-related infections' were defined as a positive blood culture plus at least one other clinical or microbiological clue such as catheter tip positivity at culture, differential time to positivity of paired peripheral and through-line blood cultures, purulent exit site, resolution of signs of infection following catheter removal and no other identifiable focus of infection.
Evaluation of mucositis
Oral mucositis was assessed for all patients using daily inspection and it was graded according to a daily mucositis score. 13 Intestinal toxicity was assessed using a modification of the ECOG Common Toxicity Criteria (CTC ECOG At ECOG.DFCI.Harvard.Edu): gastrointestinal tract toxicity was deemed as severe when 5 or more stools per day occurred.
Statistical analysis and matching
Data are expressed as mean ± s.d. (normally distributed data), median and inter-quartile range (not normally distributed data) or percent frequency (dichotomous data), and comparisons between two groups were made by t-test, Mann-Whitney test, chi-square test or exact Fisher test, as appropriate. Logistic regression was used to study factors important for various infectious end points. All calculations were done by a commercially available statistical package (StatView 5, SAS, Cary, NC, USA). Matching was done using software (NCSS 2007) provided with a matching function.
RESULTS
Factors important for infections
Factors important for infectious end points are reported in Table 2 . Three different end points were considered: 'fever438.5°C', 'severe infections (FUO, Gram-negative bacteremia or pneumonia)' and 'fever and Gram-positive bacteremia'. The factors predisposing to 'fever and Gram-positive bacteremia' were different from the factors predisposing to the other two end points, supporting the need to analyze separately the results for these end points. In our analysis, severe mucositis (grade 2-3 daily mucositis score) was an important factor, when using logistic regression, for febrile neutropenic episodes (P = 0.01).
Effects of palifermin on severe mucositis rate and on infections Palifermin was able to reduce rates of severe mucositis when evaluation was done taking into account conditioning type. In fact, in the BEAM/BUS group, we observed a significant reduction in severe mucositis rate (P = 0.03), while the reduction in severe mucositis was not significant in the HD-PAM stratum (P = 0.68). No effect of palifermin was detected on gastrointestinal toxicity, evaluated as severe diarrhea (5 or more stool passes/day, Table 3 ).
Overall, FUO rate was significantly reduced in palifermin-treated patients vs controls (20% vs 40%, P = 0.02). In the palifermin group, after BEAM/BUS, we observed (Table 4 ) also a reduction of severe infections (Gram-negative bacteremia and focal pneumonia), Abbreviations: HD-PAM = patients treated with high-dose melphalan; HTC-CI = hematopoietic cell transplantation comorbidity index.
Palifermin reduces infection rate and hyperfibrinogenemia G Milone et al which was 0% in the palifermin-treated group and 20% in matched controls (P = 0.06). When we compared the occurrence of a combined end point, 'FUO plus Gram-negative bacteremia or pneumonia', by excluding only Gram-positive infections, the palifermin group had a highly significant reduction in these types of infections (P = 0.003) as compared to the control group. This beneficial effect of Palifermin was evident also in BEAM/BUStreated patients (P = 0.01) but not in HD-PAM-treated patients (P = 0.11). In spite of this sharp reduction in severe infections, the rate of patients having fever in the palifermin group decreased, though not significantly (47.5% vs 62.5%, P = 0.19). This disagreement was sustained by a slight increase in Gram-positive infection in the Palifermin group. In fact, the rate of Gram-positive bacteremia was not reduced in patients treated with palifermin: 17.5% in the control group vs 25.0% in the palifermin-treated group (P = 0.33). Based on this observation, we hypothesized that the effect of palifermin could be different for the infections caused by Gram-negative and Gram-positive bacteria.
Effects of palifermin on plasma fibrinogen level Mean fibrinogen plasma peak during the aplastic phase was 692 mg/dL, comprising 592 mg/dL in afebrile patients vs 773 mg/ dL in febrile patients (P = 0.0001). In patients suffering from mild mucositis it was 623 mg/dL and 755 mg/dL in case of severe mucositis (P = 0.003). In the group of patients treated with palifermin, besides reduction in the rate of FUO and severe infections, we observed also a reduction in serum fibrinogen peak level (P = 0.01) registered during the aplastic phase (Table 5) .
A reduction in serum fibrinogen peak level was observed also in the stratum of patients receiving BEAM/BUS (P = 0.02) and treated with palifermin, but not in the stratum receiving HD-PAM. A significant reduction in fibrinogen level was also observed, after palifermin treatment, in the stratum of patients presenting FUO (P = 0.03).
DISCUSSION
We observed that, in patients receiving high-dose chemotherapy with HSC rescue, palifermin reduces FUO and severe infections that are not related to Gram-positive bacteria. This reduction of infections interacts significantly with conditioning, being in fact Abbreviations: DMS = daily mucositis score; HD-PAM = patients treated with high-dose melphalan. Abbreviations: FUO = fever of unknown origin; HD-PAM = patients treated with high-dose melphalan.
a Pneumonia: n = 6; Gram-negative bacteremia (Pseudomonas aeruginosa): n = 3. Coagulase-negative staphylococci: n = 22; Enterococcus faecium: n = 2. P placed between row refers to comparison within strata of control patients between groups receiving HD-PAM versus BEAM/BUS. P-values o0.05 are shown in bold. Abbreviations: CI = confidence interval; DMS = daily mucositis score; FUO = fever of unknown origin; HD-PAM = patients treated with high-dose melphalan.
more evident after conditioning based on BEAM/BUS. In the same way, also severe oral mucositis is reduced in the BEAM-BUS group, but not in HD-PAM-treated patients. These observations are fully in keeping with the data reported by Herberts on reduction of the FUO rate after paliferminin patients were treated by BEAM. 9 How can a prophylactic agent be more active based on type of conditioning? This could be due to differences in the toxicity of different drugs used in high-dose chemotherapy. Infection risk after BEAM/BUS is higher than after HD-PAM. In fact, in our control group (no palifermin), HD-PAM was associated with a reduced incidence of severe infections (FUO, Gram-negative bacteremia or pneumonia) with respect to BEAM/BUS (36.9% vs 67%, P = 0.006). The lower risk of severe infections and of FUO after HD-PAM may explain how, as in this stratum, we did not find a significant beneficial effect of palifermin, and this may contribute to explaining the interactive effect of conditioning on the relationship between palifermin and infectious risk.
However, other factors may contribute to this interaction effect. BEAM-treated patients are primarily affected by lymphoma, most of whom are in relapse at the time of ASCT and are therefore usually heavily pretreated. Patients treated with HD-PAM, on the contrary, are primarily multiple myeloma patients treated upfront after a limited amount of previous chemotherapy. A reduced infection risk of patients treated with HD-PAM may be thus independent of the conditioning itself and the conditioning in this case may play a significant role as a confounding factor.
It should be considered that high-dose PAM may have a spectrum of toxicity substantially different from 'other conditioning' and it may be associated with a higher oral toxicity, 14 and at the same time with lower gastrointestinal tract toxicity and lower infection risks. The hypothesis that oral toxicity of 'HD-PAM' is inherently different from that determined by 'other conditioning' has been already put forward by Wardley et al.
14 Such peculiar oral toxicity, not linked to severe gastrointestinal tract toxicity, may be an explanation for the inherently lower infectious risk of HD-PAM and for the lack of effect of palifermin on oral mucositis in HD-PAM-treated patients.
Fibrinogen level is a powerful prognostic factor during severe infections. 15 Therefore, the reduction in the level of fibrinogen that we found in the group receiving palifermin substantiates the beneficial clinical effect of this agent and suggests that palifermin not only reduces the rate of infections but also may determine a reduction in risk of mortality.
Prevention of infections during high-dose chemotherapy remains an unresolved issue. No drugs have been demonstrated to influence the infection rates after high-dose chemotherapy. 16 The usefulness of palifermin after high-dose chemotherapy, however, may not be considered a completely settled issue and warrants further investigations.
In particular, the effects on oral mucositis should not be considered the only clinically relevant effect of this agent; reduction of intestinal toxicity may be a more important effect of this agent, since it may be the basis for the reduced risk of some infections observed after palifermin.
Our data, as well as the data obtained by Herberts, suggest that palifermin may have a role in patients at higher risk of infections after BEAM or BUS. Use of palifermin may be particularly desirable in older patients, and in those heavily pretreated or already colonized in their gastrointestinal tract by antibiotic-resistant, Gram-negative, bacterial strains.
In conclusion, the anti-infectious beneficial effects of palifermin are more evident in BEAM/BUS-treated patients and toward some types of infections. Reduction of fibrinogen level after palifermin treatment suggests that this agent reduces not only the rate of infections but also their severity.
